A pharmacology-based meta-analysis of 152 RCTs found that different cannabinoid medications (CBD, dronabinol, nabilone, nabiximols) have distinct therapeutic profiles, with high-grade evidence only for CBD in epilepsy.
Clinicians prescribing medical cannabis, patients, researchers, and policymakers evaluating cannabinoid therapeutics.
152 RCTs analyzed; only CBD for epilepsy reached high-grade evidence
What the researchers found
CBD showed high-grade evidence for epilepsy (SMD -0.5) and moderate-grade for Parkinsonism (SMD -0.41). Dronabinol had moderate evidence for chronic pain (SMD -0.31), appetite (SMD -0.51), and Tourette syndrome (SMD -1.01). Nabiximols showed moderate evidence for chronic pain (SMD -0.25), spasticity (SMD -0.36), sleep (SMD -0.24), and substance use disorders (SMD -0.48).
Why it matters
By analyzing cannabinoid medications separately rather than lumping them together, this study reveals that the question "does cannabis work?" is misleading. The answer depends entirely on which cannabinoid and which condition.
The numbers in context
152 RCTs, 12,123 participants, 84 comparisons across 23 medical indications. Only CBD for epilepsy reached high-grade evidence. Four drug-indication combinations had moderate-grade evidence.
How the study worked
Systematic review and meta-analysis registered at PROSPERO, searching eight databases for RCTs of dronabinol, nabilone, CBD, and nabiximols across 23 medical indications. 152 RCTs with 12,123 participants were analyzed. Evidence graded using Cochrane Risk of Bias and GRADE tools.
What this study cannot tell us
Quality of included RCTs varied widely. Many indications had few trials. The meta-analysis could not account for dose optimization. Some cannabinoid-indication combinations had too few studies for robust conclusions.
How to read the evidence
Comprehensive meta-analysis with GRADE assessment. Evidence quality ranges from high to very low depending on the specific cannabinoid and indication.
When this study was published
Published in 2022.
The bigger picture
This is one of the most comprehensive pharmacology-specific analyses of medical cannabinoids to date, and its central message is clear: treating all cannabinoids as interchangeable has held back both research and clinical practice.
Questions still open
- Why do different cannabinoids work for different conditions? Would combination therapies be more effective? Are current dosing protocols optimal for each indication?
Common questions
Which cannabinoid has the strongest evidence?
Are all medical cannabis products equally effective?
Read the original research
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.
BMC medicine, 20(1), 259
Citation
Bilbao, Ainhoa; Spanagel, Rainer. (2022). Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.. BMC medicine, 20(1), 259. https://doi.org/10.1186/s12916-022-02459-1
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk